NOVEL TARGETS FOR NEW ANTIBIOTICS

BioRelix, Inc. is a market-driven company that discovers and develops antibiotics that target pathogens resistant to currently available drugs. BioRelix’ competitive advantage resides in the use of novel patented bacterial RNA targets called “RiboSwitches™” that were identified by the laboratory of BioRelix’ founder, Dr. Ronald Breaker at Yale University. MARKETS Antibiotics have long been recognized as reliable drugs that have largely overcome the lethal and devastating causes of bacterial infections. In aggregate, antibiotics generate nearly $30 billion dollars in income each year. However, patents for many of these abundantly used drugs will expire in the next few years. More importantly, all known classes of antibiotics are increasingly encountering wide-spread resistance by many prevalent bacterial pathogens that will continue to plague mankind in the 21st century. TECHNOLOGY RiboSwitches™ are short stretches of messenger RNAs that bind small metabolites and control genes that are essential for the survival of many disease-causing microbes. Yale researchers identified 14 different classes of RiboSwitch™ RNAs, and each potentially could serve as a novel antibacterial drug target. BioRelix owns a world-wise license to develop and market RiboSwitch™-target antibiotics.